12.1 Blood Composition, Hemostasis & Blood Groups

Blood Composition, Hemostasis & Blood Groups

Core Concept: Blood is the body's sole fluid connective tissue, functioning as the primary internal transport and communication medium. It continuously circulates through approximately 100,000 kilometers of blood vessels to deliver respiratory gases, metabolic nutrients, regulatory hormones, and immune defenses to every living cell while removing metabolic wastes and sustaining homeostatic fluid, electrolyte, thermal, and acid-base equilibrium.

1. Physical Properties & General Functions of Blood

In human physiology, blood is categorized as a specialized connective tissue consisting of formed cellular elements suspended within a non-living, protein-rich liquid extracellular matrix called blood plasma.

Physical Characteristics

• Viscosity: Blood is approximately 3.5 to 4.5 times more viscous (thicker and more cohesive) than pure water. This viscosity is governed primarily by circulating erythrocytes and dissolved plasma proteins; substantial increases in hematocrit elevate vascular resistance and cardiac workload, whereas severe hemodilution reduces peripheral resistance.
• Temperature: The temperature of circulating blood is roughly 38°C (100.4°F), approximately 1°C higher than measured oral or core rectal temperature. This slight elevation reflects the continuous absorption of thermal energy generated by active metabolic viscera (such as the liver and contracting skeletal muscles).
• pH & Chemical Reaction: Blood is slightly alkaline, strictly buffered within the narrow homeostatic range of pH 7.35 to 7.45 (arterial blood average: 7.40; systemic venous blood average: 7.35 due to higher dissolved carbonic acid levels). Deviations below 7.35 constitute acidosis, whereas elevations above 7.45 constitute alkalosis, both of which severely disrupt enzymatic pathways, cellular membrane stability, and central nervous function.
• Volume: In healthy human adults, total blood volume constitutes approximately 8% of total body weight:
  • Adult Males: 5 to 6 liters (elevated due to higher lean muscle mass and androgen-mediated erythropoiesis).
  • Adult Females: 4 to 5 liters.

Primary Physiological Functions

The vital responsibilities of blood are organized into three major functional domains:

1. Transportation:
   • Transports dissolved molecular oxygen ($O_2$) from pulmonary alveoli to peripheral tissue cells, and metabolic carbon dioxide ($CO_2$) from tissue cells back to the lungs for expiration.
   • Delivers absorbed nutrients (glucose, amino acids, fatty acids, vitamins, and minerals) from the digestive tract to cellular destinations.
   • Carries metabolic nitrogenous wastes (urea, uric acid, creatinine, ammonium salts, and conjugated bilirubin) to the kidneys, liver, and skin for excretion.
   • Transports endocrine hormones from ductless glands to distant target organ receptors throughout the body.
2. Regulation:
   • Thermal Balance: Distributes heat throughout the core and regulates cutaneous heat dissipation via cutaneous capillary vasodilation and vasoconstriction.
   • pH & Acid-Base Balance: Uses biological buffer systems (notably the carbonic acid-bicarbonate buffer system, plasma proteins, and hemoglobin) to neutralize excess hydrogen ions ($H^+$).
   • Fluid Volume & Osmotic Equilibrium: Maintains interstitial fluid volume and cellular hydration through dissolved electrolytes ($Na^+$, $Cl^-$) and plasma proteins (predominantly albumin).
3. Protection:
   • Hemostasis: Circulating thrombocytes and soluble clotting proteins seal ruptured vascular walls to prevent catastrophic hemorrhage.
   • Immune Defense: Circulating leukocytes, phagocytic macrophages, complement proteins, and circulating antibodies neutralize, neutralize, and destroy pathogenic bacteria, viruses, fungi, and foreign antigens.

2. Fractionation & Composition of Whole Blood

When a tube of whole blood treated with an anticoagulant (such as heparin or EDTA) is centrifuged at high speed, its cellular and liquid constituents separate cleanly based on physical density into three distinct layers:

Centrifuged Whole Blood Architecture:
┌───────────────────────────────────────────────┐
│ Top Layer: Blood Plasma (~55% of volume)      │ -> 91.5% H2O, 7% Proteins (Albumin, Globulins, Fibrinogen), 1.5% Solutes
├───────────────────────────────────────────────┤
│ Middle Layer: Buffy Coat (<1% of volume)      │ -> Leukocytes (WBCs) & Thrombocytes (Platelets)
├───────────────────────────────────────────────┤
│ Bottom Layer: Erythrocytes (~45% of volume)   │ -> Packed Cell Volume (PCV) / Hematocrit
└───────────────────────────────────────────────┘

Hematocrit (Packed Cell Volume - PCV)

The percentage of total blood volume occupied by erythrocytes is termed the hematocrit (or Packed Cell Volume [PCV]):

• Normal Adult Male Range: 42% to 52% (average ~47%).
• Normal Adult Female Range: 37% to 48% (average ~42%).
• Buffy Coat: A thin, buff-colored intermediate layer situated between the red erythrocytes and liquid plasma, representing less than 1% of total blood volume. It contains all circulating leukocytes (white blood cells) and thrombocytes (platelets).

Blood Plasma: Solute & Protein Architecture

Blood plasma is a straw-colored, viscous liquid comprising roughly 55% of total blood volume. It is composed of 91.5% water, 7.0% plasma proteins, and 1.5% dissolved electrolytes, nutrients, metabolic wastes, and regulatory substances.

Unlike cellular proteins, the majority of plasma proteins are manufactured and continuously secreted into the bloodstream by liver hepatocytes (with the critical exception of gamma globulins):

Serum vs. Plasma Distinction: Plasma is the complete liquid fraction of uncoagulated blood containing all clotting proteins. Serum is the liquid remaining after whole blood has fully clotted; it is identical in electrolyte and albumin composition to plasma but is completely devoid of fibrinogen and consumed clotting factors (Factors II, V, and VIII).

3. Formed Elements: Erythrocytes (Red Blood Cells)

Erythrocytes (RBCs) are the most abundant formed elements in human blood, specialized almost exclusively for the transport of respiratory gases.

Microscopic Anatomy & Structural Adaptations

• Biconcave Disc Morphology: Erythrocytes present as flattened, circular discs with depressed, thin centers and thickened, plump peripheries (diameter: 7.5–8.0 µm; thickness: 2.0 µm at margins, 1.0 µm at center). This shape provides an exceptionally high surface-area-to-volume ratio, accelerating the rate of gas diffusion between the interior of the cell and extracellular plasma.
• Anucleated & Devoid of Organelles: During terminal maturation in the red bone marrow, developing normoblasts extrude their nuclei and eject mitochondria, ribosomes, and the Golgi apparatus. The absence of a nucleus maximizes cytoplasmic space for hemoglobin storage. The absence of mitochondria dictates that RBCs generate cellular ATP strictly via anaerobic glycolysis, ensuring they do not consume any of the oxygen molecules they transport.
• Spectrin Cytoskeletal Flexibility: The inner cytoplasmic face of the erythrocyte plasma membrane is lined by a dynamic network of flexible cytoskeletal proteins (predominantly spectrin and actin). This network permits RBCs to dramatically fold, deform, and elongate to squeeze single-file through tortuous splenic sinusoids and narrow capillary beds (as narrow as 4–5 µm) without rupturing, springing back to their biconcave shape upon exiting.
• Normal Circulating Count:
  • Males: 4.5 to 6.0 million cells/µL (or $mm^3$).
  • Females: 4.0 to 5.0 million cells/µL.

Hemoglobin (Hb): Structure & Gas Transport

Each mature erythrocyte contains approximately 280 million hemoglobin molecules, accounting for 97% of the cell's dry weight (excluding water).

Hemoglobin Molecular Architecture:
4 Globin Polypeptide Chains (2 Alpha + 2 Beta in adult HbA)
        │
        ▼
4 Ring-shaped Porphyrin Heme Pigments
        │
        ▼
Each Heme encloses 1 Central Ferrous Iron Atom (Fe2+)
        │
        ▼
Each Fe2+ binds reversibly to 1 Molecule of O2 (Total: 4 O2 molecules per Hb)

• Quaternary Protein Structure: Adult hemoglobin (HbA) is a tetramer composed of four globular polypeptide chains: two alpha ($\alpha$) chains (141 amino acids each) and two beta ($\beta$) chains (146 amino acids each). Each globin chain cradles a non-protein, ring-shaped nitrogenous pigment called a heme group.
• Iron Complexation: At the center of each heme group lies a single reduced ferrous iron atom ($Fe^{2+}$). Because each $Fe^{2+}$ can bind reversibly to one diatomic oxygen molecule ($O_2$), a single hemoglobin tetramer can transport up to four $O_2$ molecules. One erythrocyte can carry over one billion molecules of oxygen.
• Functional Hemoglobin States:
  • Oxyhemoglobin ($Hb\text{-}O_2$): Formed in pulmonary capillaries when oxygen binds to iron; displays a relaxed molecular conformation and imparts a brilliant bright ruby-red color to arterial blood.
  • Deoxyhemoglobin (Reduced Hb): Formed in systemic capillaries when oxygen dissociates to diffuse into respiring tissues; displays a tense conformation and imparts a dark crimson/purplish color to systemic venous blood.
  • Carbaminohemoglobin ($Hb\text{-}CO_2$): Approximately 20% of metabolic carbon dioxide is transported bound directly to the terminal amino groups of the globin protein chains (not to the heme iron atoms), forming carbamino compounds.
  • Carboxyhemoglobin ($Hb\text{-}CO$): Carbon monoxide ($CO$) binds to the identical $Fe^{2+}$ binding site on heme with an affinity roughly 210 to 250 times greater than oxygen. Even minute atmospheric concentrations of $CO$ displace oxygen, producing severe tissue hypoxia, cellular suffocation, and cherry-red skin discoloration without triggering dyspnea.

Erythropoiesis: Life Cycle, Regulation & Iron Recycling

Because erythrocytes lack nuclei and protein-synthesizing machinery, they cannot divide, repair damaged structural proteins, or synthesize new enzymes. Their functional circulatory lifespan is strictly limited to approximately 120 days.

Erythropoiesis Cellular Maturation Pathway:
Pluripotent Hematopoietic Stem Cell (Hemocytoblast)
   │ (in Red Bone Marrow under EPO drive)
   ▼
Myeloid Stem Cell
   ▼
Proerythroblast (Committed Erythroid Precursor)
   ▼
Basophilic -> Polychromatic -> Orthochromatic Erythroblast (Normoblast)
   │ (Hemoglobin synthesized; Nucleus extruded)
   ▼
Reticulocyte (Enters peripheral circulation containing remnant ribosomes)
   │ (1–2 days in bloodstream)
   ▼
Mature Erythrocyte (Biconcave, anucleate, 120-day lifespan)

1. Regulation via Erythropoietin (EPO): Erythrocyte production (erythropoiesis) occurs entirely within the red bone marrow of the axial skeleton, pectoral and pelvic girdles, and proximal epiphyses of the humerus and femur. The process is governed by a classic negative feedback loop driven by hypoxia (tissue oxygen deficit):
   • When renal arterial oxygen delivery drops—due to hemorrhage, high altitude, respiratory disease, or anemia—peritubular interstitial cells in the kidneys upregulate the transcription and release of the glycoprotein hormone erythropoietin (EPO) into the circulation.
   • EPO travels to the red bone marrow, binding to surface receptors on proerythroblasts to accelerate mitotic proliferation, drive hemoglobin synthesis, and shorten the time required for erythrocyte maturation.
   • Reticulocyte Count: Immature erythrocytes that have just extruded their nucleus retain a fine network of reticular ribosomal RNA and are termed reticulocytes. They enter the circulation and mature into definitive erythrocytes within 24 to 48 hours. The normal reticulocyte count is 0.5% to 1.5% of circulating erythrocytes; a marked rise reflects accelerated bone marrow erythropoiesis following blood loss or successful iron therapy.
2. Nutritional Requirements: Erythropoiesis requires continuous dietary supplies of:
   • Iron ($Fe^{2+}$): Indispensable for heme synthesis.
   • Vitamin B12 (Cobalamin) & Folic Acid (Folate): Absolutely essential for DNA synthesis and nuclear division during rapid blast cell replication; deficiency leads to nuclear maturation arrest.
   • Amino Acids & Trace Elements: Protein for globin chains, along with copper and cobalt for enzymatic iron incorporation.
3. Erythrocyte Degradation & Hemoglobin Catabolism: As erythrocytes age, their spectrin membranes become rigid and fragile. When squeezing through the narrow (1–2 µm) vascular cords of Billroth within the spleen (the primary "RBC graveyard") and hepatic sinusoids, senescent RBCs rupture. Resident reticuloendothelial macrophages phagocytose the fragments and break down hemoglobin into its component parts:
   • Globin: Cleaved by lysosomal proteases into individual amino acids, which are released into the plasma pool for general protein synthesis.
   • Iron: Removed from the heme ring and bound to the circulating plasma transport protein transferrin. It is transported to the red bone marrow for immediate reuse or stored within the liver and spleen as intracellular protein complexes: ferritin (soluble, non-toxic storage) and hemosiderin (insoluble granular storage).
   • Non-Iron Heme: Converted by heme oxygenase into the green bile pigment biliverdin, which is rapidly reduced into the yellow-orange pigment bilirubin. Bilirubin is released into plasma, binds tightly to albumin (unconjugated / indirect bilirubin), and is extracted by the liver. Hepatocytes conjugate bilirubin with glucuronic acid to form water-soluble conjugated (direct) bilirubin, which is secreted into the duodenum via bile. In the large intestine, resident bacteria metabolize bilirubin into colorless urobilinogen; some urobilinogen is reabsorbed into blood, oxidized into urobilin, and excreted by the kidneys (producing the characteristic yellow color of urine). The vast majority of urobilinogen remains in the feces, where it is oxidized by colonic microbes into brown stercobilin, giving human stool its normal brown coloration.

Clinical Hematological Disorders

• Anemia: A clinical state characterized by an abnormally low oxygen-carrying capacity of the blood, resulting in tissue hypoxia, chronic fatigue, dyspnea, tachycardia, pallor, and cold intolerance. Pathological classifications include:
  • Iron-Deficiency Anemia: The most common worldwide form; caused by inadequate dietary intake, malabsorption, or chronic blood loss (e.g., menorrhagia, peptic ulcers). Characterized by microcytic (small) and hypochromic (pale) erythrocytes.
  • Pernicious Anemia: An autoimmune disorder targeting gastric parietal cells, eliminating the production of intrinsic factor. Without intrinsic factor, vitamin B12 cannot be absorbed in the terminal ileum, resulting in megaloblastic (macrocytic) anemia and progressive neurological degeneration.
  • Aplastic Anemia: Destruction or suppression of hematopoietic red bone marrow stem cells by ionizing radiation, toxic chemicals (benzene), medications (chloramphenicol), or viral infection, resulting in pancytopenia (simultaneous deficiency of RBCs, WBCs, and platelets).
  • Hemolytic Anemia: Premature erythrocyte lysis caused by erythrocyte membrane defects, hemoglobinopathies, mismatched blood transfusions, or bacterial toxins.
  • Sickle-Cell Disease (SCD): An autosomal recessive genetic hemoglobinopathy caused by a point mutation substituting hydrophilic glutamic acid with hydrophobic valine at position 6 of the beta-globin chain ($HbS$). Under low oxygen tensions, $HbS$ polymerizes into rigid, rod-like filaments, deforming erythrocytes into fragile, crescent-like "sickles". Sickled RBCs occlude microvascular beds, causing agonizing vaso-occlusive crises, acute chest syndrome, splenic infarction, and chronic hemolytic anemia.
• Polycythemia: An abnormal elevation in erythrocyte count and hematocrit (>55–65%), increasing blood viscosity, total peripheral resistance, and thrombosis risk:
  • Primary Polycythemia (Polycythemia Vera): A neoplastic bone marrow myeloproliferative disorder causing uncontrolled, EPO-independent erythrocyte production.
  • Secondary Polycythemia: A physiological compensatory response to chronic systemic hypoxia, seen in high-altitude residents, chronic obstructive pulmonary disease (COPD), severe cigarette smoking, or illegal exogenous EPO injection ("blood doping").

4. Formed Elements: Leukocytes & Thrombocytes

Leukocytes (White Blood Cells - WBCs)

Leukocytes are the true nucleated cells of the formed elements, possessing complete intracellular organelles and protein-synthesizing machinery. Unlike erythrocytes, leukocytes use the vascular tree primarily as a transit highway, exiting blood vessels to perform their protective functions within connective tissues.

• Normal Circulating Count: 5,000 to 10,000 cells/µL.
  • Leukocytosis: An elevated WBC count above 11,000/µL, a normal physiological response to bacterial infection, acute tissue necrosis, or strenuous exertion.
  • Leukopenia: An abnormally depressed WBC count below 4,000/µL, indicating bone marrow failure, immunosuppression, radiation damage, or viral infection (e.g., advanced HIV/AIDS).
• Characteristic Cellular Behaviors:
  • Diapedesis (Extravasation): Leukocytes roll along the endothelial wall (margination), flatten, and squeeze between adjacent endothelial cells to exit post-capillary venules into inflamed tissues.
  • Amoeboid Motility: Once in interstitial spaces, leukocytes migrate by forming cytoplasmic pseudopodia.
  • Positive Chemotaxis: Leukocytes navigate toward infection foci by following chemical concentration gradients released by damaged host cells, microbes, and inflammatory kinins.

Leukocytes are classified based on the presence and staining characteristics of conspicuous cytoplasmic granules into Granulocytes and Agranulocytes:

Leukocyte Differential Architecture (Relative Abundance Mnemonic: "Never Let Monkeys Eat Bananas"):
• Neutrophils  (60% - 70%) -> Multi-lobed nucleus, bacterial phagocytosis
• Lymphocytes  (20% - 25%) -> Large spherical nucleus, adaptive immunity
• Monocytes    (3%  - 8%)  -> Kidney-shaped nucleus, tissue macrophages
• Eosinophils  (2%  - 4%)  -> Bilobed nucleus, parasitic helminths & allergy
• Basophils    (0.5%- 1%)  -> Coarse dark granules, histamine & heparin

Thrombocytes (Platelets)

Thrombocytes are not whole cells, but small, disc-shaped, anucleated cytoplasmic fragments (diameter: 2–4 µm) essential for hemostasis.

• Normal Count: 150,000 to 400,000 platelets/µL.
  • Thrombocytopenia: Platelet count dropping below 100,000/µL (severe risk below 20,000/µL), precipitating spontaneous capillary hemorrhages across the skin (petechiae, purpura) and prolonged bleeding.
  • Thrombocytosis: Platelet count exceeding 450,000/µL, elevating the risk of unprovoked intravascular thrombosis.
• Thrombopoiesis: Produced in red bone marrow under the drive of the hepatic and renal hormone thrombopoietin (TPO). Myeloid stem cells differentiate into giant, polyploid cells called megakaryocytes (up to 100 µm diameter). Megakaryocytes extend long, filamentous cytoplasmic proplatelet ribbons through marrow sinusoid fenestrations; circulating blood shear forces fracture these ribbons into thousands of individual platelets. A single megakaryocyte yields 2,000 to 4,000 platelets.
• Lifespan & Storage: Circulate for approximately 8 to 10 days before being phagocytosed by macrophages in the spleen and liver. Roughly one-third of the body's circulating platelets are pooled and sequestered within the vascular red pulp of the spleen, ready for rapid mobilization.

5. Mechanisms of Hemostasis

Hemostasis is the rapid, localized, and tightly orchestrated sequence of physiological responses that arrests hemorrhage from an injured blood vessel while maintaining normal, clot-free fluid circulation in undamaged vasculature. It proceeds through three overlapping phases:

Chronological Stages of Hemostasis:
1. Vascular Spasm        -> Immediate local smooth muscle vasoconstriction
2. Platelet Plug         -> Adhesion, activation, degranulation (ADP/TXA2), aggregation
3. Coagulation Cascade   -> Extrinsic + Intrinsic -> Prothrombinase -> Thrombin -> Fibrin Mesh

Stage 1: Vascular Spasm (Vasoconstriction)

Immediately upon physical laceration or rupture of a blood vessel, the circular vascular smooth muscle in its tunica media contracts sharply, producing immediate local vasoconstriction that narrows the lumen and slows blood flow:

• Triggers: Triggered by direct mechanical injury to the vascular smooth muscle (myogenic spasm), chemical autacoids released by damaged endothelial cells (endothelins) and activated platelets (serotonin and thromboxane A2), and local nociceptive pain reflex arcs.
• Significance: Most effective in smaller muscular arteries and arterioles. The spasm buys valuable time (lasting 20 to 30 minutes) for the subsequent, more definitive platelet and coagulation mechanisms to deploy.

Stage 2: Platelet Plug Formation

In undamaged, healthy blood vessels, intact endothelial cells continuously produce prostacyclin ($PGI_2$) and nitric oxide (NO), which strongly inhibit platelet activation and prevent cellular adhesion. When vascular trauma denudes the endothelium, underlying subendothelial connective tissue is exposed, triggering platelet plug formation:

1. Platelet Adhesion: Circulating platelets adhere directly to exposed subendothelial collagen fibers. This adhesion is bridged and reinforced by von Willebrand factor (vWF), a large plasma glycoprotein synthesized by endothelial cells and megakaryocytes that binds simultaneously to exposed collagen and the platelet membrane surface receptor complex (glycoprotein Ib/IX/V).
2. Platelet Activation & Degranulation: Collagen binding triggers platelet activation. Platelets dramatically transform from smooth discs into irregular, spiny spheres extending long cytoplasmic pseudopodia. They discharge their intracellular storage granules:
   • Adenosine Diphosphate (ADP): A potent aggregating agent that recruits and activates neighboring circulating platelets.
   • Thromboxane A2 ($TXA_2$): A short-lived eicosanoid synthesized via platelet cyclooxygenase-1 (COX-1); powerfully amplifies local vascular spasm and induces further platelet aggregation.
   • Serotonin: Reinforces local vasoconstriction.
   • Platelet Factor 4 & PDGF: Inhibit local heparin-like compounds and stimulate fibroblasts to begin structural wound repair.
3. Platelet Aggregation: Released ADP and $TXA_2$ induce conformational activation of platelet surface glycoprotein IIb/IIIa ($GP\text{ IIb/IIIa}$) receptors. Soluble plasma fibrinogen binds to these activated receptors, acting as a molecular bridge that cross-links adjacent platelets together. Within one minute, a dense, mechanical mass called the primary platelet plug forms, sealing small capillary breaches.

Pharmacological Note — Aspirin Mechanism: Low-dose aspirin irreversibly acetylates and inactivates the platelet enzyme cyclooxygenase-1 (COX-1). Because platelets lack nuclei, they cannot synthesize new COX-1 protein; thus, platelet synthesis of thromboxane A2 ($TXA_2$) is permanently blocked for the entire 8–10 day lifespan of the platelet, significantly impairing aggregation and functioning as an effective antiplatelet prophylactic against arterial thrombosis.

Stage 3: Coagulation Cascade (Blood Clotting)

While a platelet plug can seal minor capillary leaks, larger vascular injuries require coagulation—the transformation of liquid blood into a firm, gelatinous fibrin clot. Coagulation is a complex enzymatic cascade involving over a dozen distinct plasma proteins termed clotting factors (designated by Roman numerals I through XIII in order of historical discovery, not reaction sequence). Most are synthesized by the liver and circulate as inactive zymogens; Factors II, VII, IX, and X depend upon Vitamin K for post-translational gamma-carboxylation of their glutamic acid residues.

Coagulation proceeds via two distinct initiating pathways that converge onto a shared common pathway:

• The Extrinsic Pathway (Tissue Factor Pathway):
  • Rapid and explosive, initiating clotting within 12 to 15 seconds.
  • Triggered by external trauma outside the blood vessel that breaches perivascular tissues.
  • Damaged cells release a transmembrane lipoprotein mixture called Tissue Factor (TF, also known as Factor III or Tissue Thromboplastin).
  • In the presence of ionized calcium ($Ca^{2+}$, Factor IV), TF forms an active enzymatic complex with circulating Factor VII.
  • The $TF\text{-}VIIa\text{-}Ca^{2+}$ complex directly cleaves and activates Factor X to form Factor Xa.
• The Intrinsic Pathway (Contact Activation Pathway):
  • Slower and more complex, requiring 2 to 6 minutes to initiate.
  • Triggered entirely by factors intrinsic to blood, initiated when circulating blood contacts negatively charged surfaces (such as exposed subendothelial collagen, glass, or activated platelet polyphosphates).
  • Factor XII (Hageman factor) is activated upon contact to Factor XIIa, which enzymatically activates Factor XI to Factor XIa.
  • Factor XIa activates Factor IX to Factor IXa.
  • Factor IXa complexes with activated Factor VIII (stabilized in plasma by vWF), platelet membrane phospholipids, and $Ca^{2+}$ to form the active tenase complex, which cleaves Factor X into Factor Xa.
• The Common Pathway:
  • Both the extrinsic and intrinsic pathways converge at the activation of Factor X.
  • Factor Xa combines with activated Factor V, platelet phospholipids, and $Ca^{2+}$ on the platelet surface to assemble the multi-protein enzyme complex Prothrombinase (Prothrombin Activator).
  • Prothrombinase enzymatically cleaves the inactive plasma proenzyme Prothrombin (Factor II) into the active, powerful serine protease Thrombin (Factor IIa).
  • Thrombin executes two critical terminal reactions:
    1. It cleaves soluble, circulating Fibrinogen (Factor I) into insoluble Fibrin monomers (Factor Ia). Fibrin monomers rapidly polymerize into long, insoluble, thread-like strands that form a structural web, trapping platelets and erythrocytes to construct the definitive blood clot.
    2. It activates Factor XIII (Fibrin-Stabilizing Factor) in the presence of $Ca^{2+}$, which forms covalent cross-links between adjacent fibrin strands, transforming the loose mesh into a tough, insoluble structural gel.

Clot Retraction & Fibrinolysis

Once a stable fibrin clot is established, repair and subsequent clot removal must occur:

• Clot Retraction: Within 30 to 60 minutes after clot formation, contractile proteins (actin and myosin) within the trapped platelets begin to contract. As platelets pull on the intertwined fibrin strands, the clot compacts and condenses. This contraction squeezes out serum (plasma devoid of fibrinogen and clotting factors) and pulls the severed edges of the injured blood vessel tightly together, minimizing the gap that proliferating fibroblasts and endothelial cells must bridge.
• Fibrinolysis (Clot Dissolution): A healing vessel must eventually clear the obstructive thrombus to restore normal laminar blood flow and prevent thromboembolic events. Endothelial cells synthesize and slowly secrete tissue plasminogen activator (tPA):
  • tPA converts the inactive plasma zymogen plasminogen (which was selectively incorporated into the clot during its initial formation) into the active, powerful proteolytic enzyme plasmin (fibrinolysin).
  • Plasmin digests the fibrin strands, cleaving the insoluble meshwork into soluble fibrin degradation products (FDPs), including D-dimer.
  • Elevated plasma levels of D-dimer serve as a sensitive clinical laboratory biomarker indicating active intravascular thrombosis, such as deep vein thrombosis or pulmonary embolism.

6. Blood Groups: ABO & Rhesus (Rh) Systems

The plasma membranes of human erythrocytes are genetically equipped with an array of surface glycolipid and glycoprotein antigens, termed agglutinogens. If an individual receives a blood transfusion containing foreign agglutinogens, their immune system recognizes them as non-self, activating plasma antibodies termed agglutinins that bind to the transfused cells, causing agglutination (clumping) and complement-mediated hemolysis.

The ABO Blood Group System

The ABO system is categorized based on the presence or absence of two specific carbohydrate antigens—Antigen A and Antigen B—on the erythrocyte membrane:

• Preformed Antibodies: Unlike most immune responses where antibody production requires direct antigen exposure, ABO antibodies appear spontaneously in plasma during early infancy (between 2 and 8 months of age), triggered by exposure to cross-reactive carbohydrate epitopes found on common intestinal bacteria and foods.
• Universal Donor & Recipient Concepts:
  • Type O Blood as Universal Donor: Because Type O erythrocytes completely lack surface A and B antigens, transfusing packed red blood cells of Type O into any recipient does not provoke an immediate anti-A or anti-B antibody attack. (In whole blood transfusions, donor plasma containing anti-A and anti-B antibodies is washed away).
  • Type AB Blood as Universal Recipient: Because Type AB plasma lacks both anti-A and anti-B antibodies, an individual with Type AB blood can safely receive packed red blood cells of any ABO group (A, B, AB, or O).

The Rhesus (Rh) System & Hemolytic Disease of the Newborn

The Rh system is determined by the presence or absence of the Rh D antigen (the most clinically significant of 50 Rh antigens):

• Rh-Positive ($Rh^+$): Erythrocytes carry the D antigen (roughly 85% of the Caucasian population, and higher in African and Asian populations).
• Rh-Negative ($Rh^-$): Erythrocytes lack the surface D antigen.
• Absence of Preformed Antibodies: Unlike the ABO system, an $Rh^-$ individual's plasma does not naturally contain anti-D antibodies. Anti-D antibodies develop only if the $Rh^-$ individual is sensitized by direct exposure to $Rh^+$ blood, either through an incompatible blood transfusion or via transplacental fetal-maternal microhemorrhage during pregnancy or delivery.

Hemolytic Disease of the Newborn (Erythroblastosis Fetalis) Pathogenesis:
1. First Pregnancy: Rh- Negative Mother carrying Rh+ Positive Fetus
   -> Mother exposed to fetal Rh+ RBCs during delivery/detachment
   -> Maternal immune system sensitized; generates anti-Rh (anti-D) IgG antibodies
2. Subsequent Pregnancy: Same Rh- Mother carrying another Rh+ Positive Fetus
   -> Maternal anti-Rh IgG antibodies cross placenta into fetal circulation
   -> Anti-Rh antibodies bind and destroy fetal Rh+ RBCs
   -> Severe fetal hemolytic anemia, hyperbilirubinemia, hydrops fetalis
3. Clinical Prevention: Administer RhoGAM (anti-D immunoglobulin) at 28 weeks & within 72h postpartum

• Erythroblastosis Fetalis (HDN): Occurs when an $Rh^-$ mother carries a second or subsequent $Rh^+$ fetus. During the first delivery, maternal exposure to fetal $Rh^+$ blood sensitizes maternal B cells, which produce anti-Rh IgG antibodies. Because IgG antibodies are small monomeric immunoglobulins that cross the placental barrier, in a subsequent pregnancy with an $Rh^+$ fetus, maternal anti-Rh antibodies enter the fetal circulation and target the fetal erythrocytes for massive hemolysis. This produces profound fetal anemia, hepatosplenomegaly, severe jaundice (unconjugated bilirubin accumulation causing toxic kernicterus in the basal ganglia of the brain), and potential fetal death (hydrops fetalis).
• Clinical Prevention via RhoGAM: HDN is routinely prevented by administering RhoGAM (anti-D immune globulin) to all unsensitized $Rh^-$ mothers at 28 weeks of gestation and within 72 hours following delivery, miscarriage, abortion, or amniocentesis. RhoGAM consists of exogenous anti-D antibodies that bind and clear any circulating fetal $Rh^+$ erythrocytes before the maternal immune system can recognize them, completely preventing maternal sensitization.

7. Clinical & Therapist Practice Applications

Practitioners of bodywork, manual therapy, and clinical aesthetics regularly encounter clients with hematological imbalances, vascular fragility, and pharmacological anticoagulation. Safe practice requires recognizing these conditions and modifying treatments accordingly:

• Anemia Considerations: Clients presenting with chronic anemia exhibit reduced exercise tolerance, systemic fatigue, postural dizziness, and cold sensitivity due to peripheral vasoconstriction. Treatments should focus on gentle, parasympathetic-inducing strokes. Vigorous, rapid, or exhaustive deep tissue techniques must be avoided because tissues are already suboptimally oxygenated. Maintain ambient room warmth and provide adequate blankets to prevent hypothermia.
• Bleeding Disorders & Hemophilia: Inherited coagulopathies—such as Hemophilia A (Factor VIII deficiency), Hemophilia B (Factor IX deficiency), or severe thrombocytopenia—represent an absolute contraindication to deep tissue massage, vigorous petrissage, percussive tapotement, and intense myofascial stripping. Strong mechanical forces can rupture fragile capillaries, inducing severe, uncontrolled intramuscular hematomas, internal hemorrhages, and disabling bleeding into synovial joints (hemarthrosis).
• Anticoagulant & Antiplatelet Pharmacotherapy: Millions of clients take prescription blood thinners, including vitamin K antagonists (warfarin / Coumadin), direct thrombin inhibitors (dabigatran), direct factor Xa inhibitors (apixaban / Eliquis, rivaroxaban / Xarelto), or antiplatelet agents (aspirin, clopidogrel / Plavix). These medications delay coagulation and significantly increase the risk of bruising. Therapists must modify techniques to light-to-moderate pressure, avoiding aggressive frictions, ischemic compressions, or deep cross-fiber techniques.
• Ecchymosis & Local Hematomas: A localized bruise (ecchymosis) represents blood extravasation into the dermis and subcutaneous tissue following capillary rupture, while a hematoma is a localized collection of clotted blood within tissue planes. Deep pressure directly over an acute, tender hematoma is locally contraindicated because mechanical pressure can re-injure disrupted vessels, aggravate inflammation, or promote dystrophic calcification (myositis ossificans). Gentle effleurage directed toward the heart proximal to the bruise is permitted to assist lymphatic clearance of degraded hemoglobin pigments.

Clinical Trap — The Universal Donor Paradox: Never confuse whole blood versus packed red blood cell donor rules. In emergency medicine, Type O-negative packed red blood cells are the universal donor because the cells lack A, B, and Rh antigens, presenting no targets for recipient antibodies. However, Type AB plasma is the universal donor for plasma transfusions because it contains neither anti-A nor anti-B antibodies, ensuring it will not attack recipient erythrocytes.